Research programme: cancer vaccines - Geovax

Drug Profile

Research programme: cancer vaccines - Geovax

Alternative Names: GEO CM 01; MVA-VLP cancer vaccine - GeoVax Labs; MVA-VLP-MUC1

Latest Information Update: 04 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GeoVax Labs
  • Developer GeoVax Labs; University of North Carolina at Chapel Hill; University of Pittsburgh
  • Class Cancer vaccines; DNA vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants; Mucin 1 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 30 Aug 2017 Preclinical trials in Cancer (Prevention) in USA (Parenteral)
  • 11 Nov 2016 GeoVax and ViaMune co-develop cancer vaccines in USA
  • 09 Feb 2016 GeoVax labs and University of Pittsburgh agree to co-develop cancer vaccines in USA for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top